S039 What's New in Dermatopathology
DESCRIPTION
This symposium provides information regarding advances in key areas of dermatopathology. Cutaneous neoplasia, inflammatory skin disease, dermoscopy, molecular techniques, translational research, and cutaneous infections will be covered. Attendees will leave the session with updated knowledge in dermatopathology.
LEARNING OBJECTIVES
Describe new advances in cutaneous neoplasia, including melanocytic tumors and adnexal neoplasms
Discuss recent developments in immunobullous disorders and cutaneous drug reactions
Describe need-to-know patterns of dermoscopy.
SCHEDULE
1:00 PM
Introduction
Jeffrey P. North, MD, FAAD
1:05 PM
Updates in immunodermatology
Julia S. Lehman, MD, FAAD
1:25 PM
Updates in cutaneous drug reactions
Emily Y. Chu, MD, PhD, FAAD
1:45 PM
Granulomas gone wild: Rubella as a trigger in granulomatous disease
Karolyn Wanat, MD, FAAD
2:05 PM
Updates in diagnosing pigmentary disorders
Anisha Patel, MD, FAAD
2:25 PM
Q&A
Emily Y. Chu, MD, PhD, FAAD, Julia S. Lehman, MD, FAAD, Anisha Patel, MD, FAAD, Karolyn Wanat, MD, FAAD
2:40 PM
Updates in melanocytic neoplasia
Iwei Yeh, MD, PhD, FAAD
3:00 PM
Updates in Inpatient dermatopathology
Kiran Motaparthi, MD, FAAD
3:20 PM
Correlating histopathology with dermoscopy
Michelle B Tarbox, MD, FAAD
3:40 PM
Q&A
Kiran Motaparthi, MD, FAAD, Michelle B Tarbox, MD, FAAD, Iwei Yeh, MD, PhD, FAAD
DIRECTOR
Jeffrey P. North, MD, FAAD
SPEAKERS
Emily Y. Chu, MD, PhD, FAAD
Julia S. Lehman, MD, FAAD
Kiran Motaparthi, MD, FAAD
Anisha Patel, MD, FAAD
Michelle B Tarbox, MD, FAAD
Karolyn Wanat, MD, FAAD
Iwei Yeh, MD, PhD, FAAD
HANDOUTS
DISCLOSURES
Emily Y. Chu, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Julia S. Lehman, MD, FAAD
No financial relationships exist with ineligible companies.
Kiran Motaparthi, MD, FAAD
No financial relationships exist with ineligible companies.
Jeffrey P. North, MD, FAAD
Johnson & Johnson Pharmaceutical Research & Development – Consultant (1099 relationship)(Fees);
Anisha Patel, MD, FAAD
Astellas Pharma US, Inc – Consultant (1099 relationship)(Fees); Asymmetric Therapeutics, LLC – Consultant (1099 relationship)(Fees); Deciphera Pharmaceuticals, Inc. – Consultant (1099 relationship)(Fees); EMD Serono – Advisory Board(Fees); Erasca – Consultant (1099 relationship)(Fees); FBIO Acquisition Corp LXI – Consultant (1099 relationship)(Stock); Hoth Therapeutics – Investigator(Grants/Research Funding); IDEOlogy Health – Consultant (1099 relationship)(Fees); Janssen Scientific Affairs, LLC – Consultant (1099 relationship)(Fees); Lutris – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Revolution Medicines – Advisory Board(Fees); Roche Pharma – Consultant (1099 relationship)(Fees); SynOx Therapeutics – Consultant (1099 relationship)(Fees); UpToDate, Inc – Other(Patent royalties or other compensation for Intellectual Property Rights);
Michelle B Tarbox, MD, FAAD
AbbVie – Advisory Board(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria); Castle Biosciences – Investigator(Grants/Research Funding); Dermaleve – Advisory Board(Honoraria); Eli Lilly – Advisory Board(Honoraria); Galderma – Speaker(Honoraria); Leo Pharma – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria); Sanofi/Regeneron – Investigator(Grants/Research Funding); UCB – Advisory Board(Honoraria);
Karolyn Wanat, MD, FAAD
No financial relationships exist with ineligible companies.
Iwei Yeh, MD, PhD, FAAD
Pfizer Inc. – Investigator(Grants/Research Funding);